NCT05901636: A reported trial by Janssen Vaccines & Prevention B.V.
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT05901636 |
|---|---|
| Title | A Randomized, Double-blind, Placebo-controlled, First-in-human Phase 1/2a Study to Evaluate Safety, Reactogenicity and Immunogenicity of a Universal Influenza (Uniflu) Vaccine With INFLUENZA G1 mHA in Healthy Adults |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | May 17, 2023 |
| Completion date | Aug. 19, 2024 |
| Required reporting date | Aug. 19, 2025, midnight |
| Actual reporting date | Aug. 18, 2025 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |